A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis (nrSPMS).
The Phase 3 HERCULES trial showed tolebrutinib, an oral Bruton's tyrosine kinase (BTK) inhibitor, delayed the time to onset of 6-month confirmed disability progression by 31% compared with placebo.
In addition, tolebrutinib almost doubled the number of patients who experienced confirmed disability improvement from 5% to 10%.
I have non relapsing spms and was part of the Hercules study. It ended in June☹️ but I felt my best. It was a double blind study so I don't know if I was getting the drug or placebo. All I know is that's the drug I want to take when the FDA passes it hopefully sooner rather than later
I hope it passes quickly for all of our sakes!! So glad it made you better 💐
so when the study ended i decided to take mavenclad . i did year one but i haven't felt that great...no energy or desire to do anything and just weak. first dose was in july and second dose in august.
That's too bad. How long were you on the tolebrutinib (assuming you weren't on the placebo)?
the study was about 3 yrs being double blind i don't know if i was taking the drug or not. i had no side effects and my mri's and bloodwork were stable throughout that time. might be next year before i find out if i was on drug or placebo. i did read the tolebrutinib would probably come out the second half of 2025😔
I’m so sorry you haven’t felt great.. 🙏🏼🤗🙏🏼
Exciting news, thanks for posting!
Thank you for sharing. Leslie
I have Primary MS. I have not read but will ask. Thanks
Looking for answers
New to blogs, old in MS
Lemtrada
First-Line Rituximab Bests Other MS Drugs in Sweden
